FindTrial
Sign In

Investigation of efficacy and safety of implementation of genetic and platelet function testing for guiding antiplatelet therapy (GF-APT) after percutaneous coronary intervention

Investigation of efficacy and safety of implementation of genetic and platelet function testing for guiding antiplatelet therapy (GF-APT) after percutaneous coronary intervention

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100047090
Enrollment
Unknown
Registered
2021-06-08
Start date
2021-07-01
Completion date
Unknown
Last updated
2022-01-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary atherosclerotic heart disease

Interventions

Case series:N/A

Sponsors

Fuwai Hospital, CAMS&PUMC
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Undergoing PCI with stent implantation for ACS or stable coronary heart disease; 2. Sufficient clinical information, including the patient's basic characteristics and treatment information; 3. Planing to receive DAPT treatment for 1 year after procedure.

Exclusion criteria

Exclusion criteria: 1. History of atrial fibrillation, valvular disease and indications to the use of other oral anticoagulant; 2. Any contraindication to the use of P2Y12 receptor antagonist; 3. A life expectancy of <1 year ; 4. Prior knowledge of the patients' CYP2C19 genotype.

Design outcomes

Primary

MeasureTime frame
Major cardiovascular adverse event;—

Secondary

MeasureTime frame
Bleeding Events;—

Countries

China

Contacts

Public ContactQiu Hong

Fuwai Hospital, CAMS&PUMC

qiuhong6780@sina.com+86 13261179000

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026